We found that all tumor cells share the vast majority of these mutations (i.e., they are clonal), including variants affecting genes previously associated with CRC progression (e.g., INPP1, CDC5L, ROR2, EXOSC5) [62–65]. This evidence concerns the gene ROR2 and neoplasm.